Merck reported strong Q4 results with record sales and significant cost reductions, indicating solid current performance. However, the withdrawal of long-term guidance due to macroeconomic uncertainties introduces short-term uncertainty. Overall, the strong immediate results are likely to outweigh the guidance concerns in the near term.

\[1\]